What's Happening?
Eli Lilly's RET inhibitor, Retevmo (selpercatinib), has demonstrated significant efficacy in the LIBRETTO-432 trial for patients with early-stage RET fusion-positive non-small cell lung cancer (NSCLC). The trial revealed an 83% reduction in the risk of
cancer recurrence when Retevmo was used as an adjuvant treatment compared to a placebo. The study involved 151 patients who had undergone surgery or radiotherapy, with some also receiving adjuvant chemotherapy. Notably, 92% of patients on Retevmo were alive and cancer-free after two years, compared to 61% on placebo. Retevmo is already FDA-approved for advanced RET-positive lung and thyroid cancers, and this trial positions it as a potential new standard of care for early-stage NSCLC.
Why It's Important?
The findings from the LIBRETTO-432 trial could significantly impact the treatment landscape for early-stage NSCLC, offering a new standard of care that reduces the risk of cancer recurrence. This is particularly crucial as early-stage lung cancer patients often face high recurrence rates despite curative surgery or radiation. The trial underscores the importance of genetic testing at diagnosis to tailor treatments effectively. Retevmo's success in this trial could expand its market presence and provide a more effective treatment option for a broader patient population, potentially improving survival rates and quality of life for those affected by this type of cancer.
What's Next?
Following the promising results of the LIBRETTO-432 trial, Eli Lilly may seek to expand the indications for Retevmo to include early-stage NSCLC. This could involve further regulatory submissions and potential label expansions. The success of this trial may also prompt additional research into the use of RET inhibitors in other cancer types or stages. As the drug moves into earlier treatment settings, it could become a more integral part of lung cancer management, influencing treatment guidelines and practices. Continued monitoring of long-term outcomes and potential side effects will be essential to fully understand the benefits and risks of Retevmo in this new context.
